Beijing Peking University WBL Biotech Co.
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Beijing Peking University WBL Biotech Co. sits in the upper half of US sponsors by registered trial count (#7,389 of 15,742 sponsors by registered trial count).
Beijing Peking University WBL Biotech Co.: 1 sponsored US clinical trial, none currently recruiting.
Beijing Peking University WBL Biotech Co. sponsors 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hyperlipidemia, with 1 trials.
Mid-pack sponsor footprint
Beijing Peking University WBL Biotech Co. is in the upper half of sponsors by trial count (#7,389 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Indexed trials (enrollment closed)
1 total, page 1 of 1
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
Therapeutic Areas
How the Beijing Peking University WBL Biotech Co. early-phase archive is shaped
1 indexed studies, none listed as recruiting (0% open); 1 completed (100%).
Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).
Top condition: Hyperlipidemia (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Beijing Peking University WBL Biotech Co.: archived-pipeline peers nationwide
Peers matched on 1 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Beijing Peking University WBL Biotech Co. sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1 archived trials
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Beijing Peking University WBL Biotech Co. page
1 registered trials is a research-attention snapshot, not an endorsement of Beijing Peking University WBL Biotech Co. or any single study.
- None of Beijing Peking University WBL Biotech Co.'s trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Hyperlipidemia is the condition Beijing Peking University WBL Biotech Co. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hyperlipidemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Beijing Peking University WBL Biotech Co. pipeline card: 1 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.